ALLMedicine™ Anaplastic Oligoastrocytoma Center

Jul 16th, 2020 - Practice Essentials Oligodendroglioma is a well-differentiated, diffusely infiltrating tumor of adults that is typically located in the cerebral hemispheres and is predominantly composed of cells that morphologically resemble oligodendroglia. [1, ...

Jul 16th, 2020 - Practice Essentials Oligodendroglioma is a well-differentiated, diffusely infiltrating tumor of adults that is typically located in the cerebral hemispheres and is predominantly composed of cells that morphologically resemble oligodendroglia. [1, ...

Nov 22nd, 2018 - Extracranial metastasis is a rare phenomenon of anaplastic oligoastrocytoma. When patients progress after comprehensive treatment, there is often no effective treatment. Rapid development of gene detection technology makes precision treatment of g...

Sep 15th, 2018 - Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare but lethal complication of carcinoma, defined as non-occlusive pulmonary tumor embolism complicated by fibrocellular intimal proliferation of the small pulmonary arteries, with eventual o...

Oct 24th, 2017 - The SEOM/GEINO clinical guidelines provide recommendations for radiological, and molecular diagnosis, treatment and follow-up of adult patients with anaplastic gliomas (AG). We followed the 2016 WHO classification which specifies the major diagnos...

Oct 24th, 2017 - The SEOM/GEINO clinical guidelines provide recommendations for radiological, and molecular diagnosis, treatment and follow-up of adult patients with anaplastic gliomas (AG). We followed the 2016 WHO classification which specifies the major diagnos...

Mar 14th, 2017 - Phase I Primary Objective • To determine the maximum tolerated dose (MTD) of LBH589 in combination with bevacizumab given at 10 mg/kg every 2 weeks in patients with recurrent glioblastoma (GBM), gliosarcoma, anaplastic astrocytoma, anaplastic olig...

Sep 13th, 2012 - OBJECTIVES: I. Determine the median time to progression, median survival, and objective response of patients with anaplastic astrocytoma or anaplastic oligoastrocytoma in first relapse treated with intravenous leflunomide (SU101). II. Assess the s...

Dec 20th, 2020 - Timothy Cloughesy, MD The gene for an anticancer drug was successfully transduced in high-grade gliomas, according to data from a phase I trial of Toca 511 presented at the 2016 Society for Neuro-Oncology Annual Meeting. Additionally, the median ...

Dec 5th, 2020 - The carcinoembryonic antigen (CEA) vaccinia has been researched for more than 20 years. Investigational Glioma Vaccine Results Promising A novel vaccine based on dendritic cells and peptides proved to be safe and capable of delivering an im...

Dec 5th, 2020 - Victor A. Levin, MD Eflornithine (α-Difluoromethylornithine) has been investigated for over 30 years as a potential neuro-oncology agent and shown activity against recurrent gliomas, but it has not gained approval as a therapy option for patients...

Dec 5th, 2020 - Victor A. Levin, MD Investigators are seeking to determine whether the combination of eflornithine (alphadifluoromethylornithine) with lomustine can improve survival for patients with recurrent anaplastic astrocytoma (AA). A rare form of brain tu...